Jump to main content
Jump to site search


Co-administration of Genistein with Doxorubicin-Loaded Polypeptide Nanoparticles Weakens the Metastasis of Malignant Prostate Cancer by Amplifying Oxidative Damage

Abstract

Prostate cancer is one typical malignant disease with a high incidence and a poor prognosis. Doxorubicin hydrochloride (DOX•HCl) is one of the most effective agents in the treatment of prostate cancer, however, its severe side effects and metastasis after its treatment impose restrictions on its application. Herein, a combination of genistein (GEN) and doxorubicin hydrochloride-loaded polypeptide nanoparticles (DOX-NPs) is constructed for the treatment of prostate cancer. The DOX-NPs can reduce the side effects of free DOX•HCl and produce relatively low level of intracellular reactive oxygen species (ROS)-induced oxidative damage. While the GEN, an inhibitor of oxidative DNA repair enzyme apurinic/apyrimidinic endonuclease1 (APE1), can further amplify ROS-induced oxidative damage by downregulating the intracellular expression of APE1 and reducing oxidative DNA repair in the prostate cancer cells. Because high level of ROS-induced oxidative damage can prevent distant metastasis of tumor cells, the distant metastasis of malignant prostate cancer cells is significantly inhibited by the combination of genistein and DOX-NPs with amplifying oxidative damage.

Back to tab navigation

Supplementary files

Publication details

The article was received on 22 Dec 2017, accepted on 08 Feb 2018 and first published on 12 Feb 2018


Article type: Paper
DOI: 10.1039/C7BM01201B
Citation: Biomater. Sci., 2018, Accepted Manuscript
  •   Request permissions

    Co-administration of Genistein with Doxorubicin-Loaded Polypeptide Nanoparticles Weakens the Metastasis of Malignant Prostate Cancer by Amplifying Oxidative Damage

    G. Wang, D. Zhang, S. Yang, Y. Wang, Z. Tang and X. Fu, Biomater. Sci., 2018, Accepted Manuscript , DOI: 10.1039/C7BM01201B

Search articles by author

Spotlight

Advertisements